LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

Home・Aktien・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

38.79 1.62

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

37.92

Max

39.41

Schlüsselkennzahlen
By Trading Economics
Einkommen	-20M -85M
Gewinnspanne	-867.293
Angestellte	316
EBITDA	4.1M -73M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+42.48% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	11. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	299M 2.9B
Vorheriger Eröffnungskurs	37.17
Vorheriger Schlusskurs	38.79

Nachrichtenstimmung

By Acuity

67%

33%

333 / 372 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

34.81 / 38.24 Unterstützung & Widerstand

Xenon Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Aug. 2025, 23:09 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 4th Update

22. Aug. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

Agreement Could Also Lead to Deeper Collaboration Between CSX, BNSF

22. Aug. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

Some Analysts Say Agreement Suggests Lack of Confidence in Merger

22. Aug. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

CSX, BNSF Intermodal Pact Draws Competing Views on Merger Possibility

22. Aug. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

CSX, BNSF Pact Sparks Debate on Whether Another Rail Merger Is Approaching -- Analysis

22. Aug. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

Pact Could Show Regulators That Transcontinental Service Can Come Without Merger

22. Aug. 2025, 21:23 UTC

Market Talk

Moody's Lowers Outlook on Austria to Negative From Stable -- Market Talk

22. Aug. 2025, 21:18 UTC

Market Talk

US Economic Growth Seen Slowing This Year -- Market Talk

22. Aug. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Takes 10% Stake in Intel -- Barrons.com

22. Aug. 2025, 21:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. Aug. 2025, 21:03 UTC

Market Talk

Mexican Stocks Close At Record High -- Market Talk

22. Aug. 2025, 20:58 UTC

Market Talk

US General Government Deficit Expected to Rise in 2026, 2027 -- Market Talk

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: Government's Investment in Intel Will Be a Passive Ownership, With No Bd Representation or Other Governance or Info Rights >INTC

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: Government Also Agrees to Vote With the Company's Bd of Directors on Matters Requiring Shareholder Approval, With Limited Exceptions >INTC

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: Government Equity Stake Will Be Funded by Remaining $5.7B in Grants Previously Awarded, But Not Yet Paid, Under U.S. CHIPS and Science Act and $3.2B Awarded as Part of Secure Enclave Program >INTC

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: Government Agrees to Purchase 433.3M Primary Shrs of Intel Common Stk at a Price of $20.47 per Shr, Equivalent to a 9.9% Stake in Co >INTC

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: U.S. Government to Make $8.9B Investment in Intel Common Stk as Co Builds Upon Its More Than $100B Expansion of Resilient Semiconductor Supply Chain >INTC

22. Aug. 2025, 20:57 UTC

Akquisitionen, Fusionen, Übernahmen

Intel: Intel and Trump Admin Reach Historic Agreement to Accelerate Amer Technology and Manufacturing Leadership

22. Aug. 2025, 20:56 UTC

Ergebnisse

These Stocks Moved the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22. Aug. 2025, 20:55 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22. Aug. 2025, 20:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

22. Aug. 2025, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

22. Aug. 2025, 20:41 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Has 10% Stake in Intel, Lutnick Says -- Barrons.com

22. Aug. 2025, 20:24 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 3rd Update

22. Aug. 2025, 20:16 UTC

Akquisitionen, Fusionen, Übernahmen

CSX and Warren Buffett's BNSF Made News. Why Investors Are Disappointed. -- Barrons.com

22. Aug. 2025, 19:19 UTC

Market Talk

Boeing to Restart Talks With Defense Workers' Union Monday -- Market Talk

22. Aug. 2025, 19:10 UTC

Market Talk

Oil Futures Gain as Russia-Ukraine Peace Seems Distant -- Market Talk

22. Aug. 2025, 19:06 UTC

Market Talk

U.S. Natural Gas Extends Losses as Summer Nears an End -- Market Talk

22. Aug. 2025, 19:03 UTC

Market Talk

Lower Borrowing Rates Elusive Even if Fed Cuts -- Market Talk

22. Aug. 2025, 18:52 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 2nd Update

Peer-Vergleich

Kursveränderung

Xenon Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

42.48% Vorteil

12-Monats-Prognose

Durchschnitt 54.4 USD 42.48%

Hoch 65 USD

Tief 47 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Xenon Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Xenon Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

34.81 / 38.24Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Stimmung

By Acuity

333 / 372 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.